NYSE$EVH

Evolent Health Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Evolent Health reported strong Q4 2023 results, achieving financial objectives with revenue growth and successful integration of NIA.

Evolent Health announced its Q4 and Full Year 2023 results, with Q4 revenue reaching $556.06 million and a net loss of $41.40 million. The company achieved all financial objectives for the year, driven by underlying growth and the successful integration of NIA. The company is providing initial outlook for 2024 in line with long-term targets.

  • Q4 revenue reached $556.06 million.
  • Net loss attributable to common shareholders was $(41.40) million.
  • Adjusted EBITDA was $48.06 million.
  • The company signed four new revenue agreements for 2024, reflecting success in value-based specialty care.

Headline financials

Total Revenue

$556M

Previous: $382M+45.4%
EPS (adj)

$0.23

Previous: $0.10+130.0%
Capital Expenditures

-$6.05M

No prior period
Free Cash Flow

$83.3M

No prior period
Net Income

-$41.4M

Previous: -$11.3M-266.3%
Operating Income

-$21.4M

Previous: -$1.88M-1036.8%
Gross Profit

$102M

Previous: $83.1M+22.3%
Stock-Based Comp

$10.6M

Previous: $14.6M-27.5%

Revenue & EPS history

Evolent Health · Revenue · Quarterly

$556M

Q4 2023+45.4%vs Q4 2022
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Revenue by segment

Evolent Health · $92.7M total across 3 segments · Q3 2023

  • Cases
    $37.4M
  • Performance Suite
    $32.8M
  • Administrative Services
    $22.5M

Forward guidance

For the year ending December 31, 2024, revenue is expected to be in the range of approximately $2.4 billion to $2.5 billion and Adjusted EBITDA is expected to be in the range of approximately $235 million to $265 million.

Tailwinds

  • Revenue is expected to be in the range of approximately $2.4 billion to $2.5 billion.
  • Adjusted EBITDA is expected to be in the range of approximately $235 million to $265 million.
  • Cash deployed for capitalized software development of approximately $30 million.
  • Cash flow from operations to exceed $150 million.
  • Initial financial outlook for 2024 includes revenue growth of 25% at the midpoint, exceeds multi-year revenue and profit growth targets.

Headwinds

  • The company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort.
  • Future period non-GAAP guidance includes adjustments for items not indicative of our core operations.
  • Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations.
  • The exact amount of these adjustments are not currently determinable but may be significant.
  • Actual results may differ materially.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+2.2%

Avg return

Earnings day

+1.2%

Avg return

5 days after

-1.9%

Avg return

30 days after

65%

32 / 49 earnings

Positive

+29.2%

Q2 2024

Best reaction

-46.1%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+11.5%+8.6%+9.9%
Q4 2025+25.0%+39.8%-13.7%
Q3 2025-17.5%-25.8%-34.3%
Q1 2025-16.2%-17.1%-22.7%
Q4 2024-2.6%-11.8%-10.6%
Q3 2024-46.1%-41.7%-55.0%
Q2 2024+29.2%+28.5%+49.3%
Q1 2024-10.3%-12.5%-13.9%
Q4 2023+13.8%+14.1%+8.3%
Q3 2023+13.5%+18.4%+20.4%
Q2 2023-7.5%-4.6%-14.2%
Q1 2023-4.3%-0.9%-11.4%
Q4 2022+9.1%+9.0%-4.4%
Q3 2022-10.8%-22.4%-1.2%
Q2 2022+4.9%+2.7%+6.2%
Q1 2022+0.9%-8.5%+4.0%
Q4 2021+13.9%+16.4%+34.8%
Q3 2021+3.4%+0.3%-10.4%
Q2 2021+3.5%+2.9%+13.5%
Q1 2021+8.2%+11.7%+5.2%
Q4 2020-3.1%-6.9%-0.9%
Q3 2020+6.9%+15.3%+41.0%
Q2 2020+8.3%+8.8%+13.7%
Q1 2020+12.6%+11.4%-1.6%
Q4 2019-13.7%-18.2%-48.0%
Q3 2019+16.3%+29.7%-14.4%
Q2 2019+9.3%+17.2%+13.4%
Q1 2019-1.3%+0.9%-34.6%
Q4 2018-3.5%-8.8%-14.2%
Q3 2018+14.5%+10.8%-8.5%
Q2 2018+1.4%+5.0%+17.2%
Q1 2018+8.4%+12.8%+36.4%
Q4 2017+1.0%+5.5%-1.7%
Q3 2017-13.4%-27.5%-16.0%
Q2 2017-17.6%-23.7%-25.9%
Q1 2017+3.3%+5.0%+14.2%
Q4 2016+5.7%+1.2%+8.0%
Q3 2016-3.1%-9.7%-13.9%
Q2 2016+3.8%+9.6%+3.1%
Q1 2015+0.7%
Q1 2016+14.5%
Q4 2013+3.9%
Q1 2014+3.9%
Q2 2015+3.9%
Q4 2015+14.6%
Q3 2014+12.0%
Q3 2015+11.8%
Q2 2014-8.5%
Q4 2014-8.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro